Skip to main content

Apremilast News

FDA Approves Otezla (apremilast) for the Treatment of Adult Patients with Plaque Psoriasis, Regardless of Severity Level

THOUSAND OAKS, Calif., Dec. 20, 2021 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla® (apremilast) for the treatment of adult ...

FDA Approves Otezla (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease

SUMMIT, N.J.--(BUSINESS WIRE) July 19, 2019 – Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast) 30 mg twice daily (BID) for the...

FDA Approves Otezla (apremilast) for Moderate to Severe Plaque Psoriasis

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast), the Company's oral, selective inhibitor of...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Psoriatic Arthritis, Plaque Psoriasis, Psoriasis

Related drug support groups

Otezla

Apremilast patient information at Drugs.com